Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT Clinical Trials at SNMMI Annual Meeting (GlobeNewswire) - Jun 29, 2023 - P1/2 | N=55 | ReSPECT-GBM (NCT01906385) | Sponsor: Plus Therapeutics | "Plus Therapeutics...reported positive interim updates from the ReSPECT-GBM...clinical studies evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda...at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting....An oral presentation titled, Safety and Feasibility Results from a Phase 1/2 Clinical Trial of 186RNL (Rhenium-186 Nanoliposome) (186Re) Obisbemeda in Recurrent Glioma: The ReSPECT-GBM Trial [P988], brief highlights include:...The data demonstrates efficacy signals in a prognostically unfavorable patient population. The median overall survival (OS) in all 21 patients...was 11 months or a 38% increase in OS versus a median OS of approximately 8 months for standard of care in rGBM. Median OS in patients receiving >100 Gy of absorbed radiation dose was 76 weeks (17 months) versus 22 weeks (6 months) for those receiving <100 Gy (p=0.0002)."
P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|